Avelumab plus axitinib combination shows promise

A clinical trial looking at the combination of avelumab plus axitinib for renal cell carcinoma (RCC), JAVELIN Renal 101, has released some positive top-line results, which will be presented at an upcoming medical congress. JAVELIN Renal 101 is a pivotal phase III study with 886 renal cancer patients. As part of a planned interim analysis, […]

read more

Joint statement from the EAU and IKCC about the rejection of the ipilimumab plus nivolumab combination for kidney cancer by the EMA

The European Association of Urology (EAU) Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition (IKCC) have issued a joint statement about the rejection of ipilimumab and nivolumab for kidney cancer by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The EAU are saying that the CHMP’s decision […]

read more

Stereotactic body radiotherapy may improve control of localised kidney cancer

A recent study published in The Journal of Urology this month suggests that stereotactic body radiotherapy (SBRT) may be a safe and effective therapeutic option that could control the growth of localised, small numbers of metastases (oligometastatic) in people with advanced renal cell carcinoma (RCC). Fifty-eight RCC patients, who had undergone surgery and had a maximum […]

read more

Patients are willing to share personal data with the NHS, but not pharma

This blog starts with the results of a survey of 2000 people, 56% of which said they would be happy to share personal data with the NHS if it led to better services. But only 15% of those surveyed said they would be prepared to share personal data with pharmaceutical companies. The blog goes on to […]

read more

Contrast-enhanced ultrasound helps diagnose kidney cancer

A 10-year study presented at an international medical conference in Chicago this week suggests that an enhanced ultrasound scan of the kidney is more accurate than computed tomography and magnetic resonance imaging in predicting cancer. Using microbubbles as a contrast agent, ultrasound can thus eliminate the need for unnecessary biopsies and surgeries in some patients. […]

read more

Adjuvant sunitinib may increase symptoms and reduce quality of life in kidney cancer

A recent article in Annals of Oncology reports new patient-reported outcomes data from the S-TRAC study to suggest that adjuvant sunitinib treatment in patients with a high risk of recurrence of renal cell carcinoma (RCC) was linked to increased symptoms and a worse health-related quality of life (HRQoL) compared with placebo. The S-TRAC study showed that […]

read more
Showing 1 to 6 of 433 results
  TOP